To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension

Study identifier:D1020C00012

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Open, Two-Way Cross-Over, Single-Centre, Phase I Study to Assess the Counter regulatory Response during Hypoglycaemia in Healthy Male Volunteers after a Single Oral Dose of AZD1656 Suspension in Comparison with Insulin Infusion

Medical condition

Type 2 Diabetes

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Insulin, AZD1656

Sex

Male

Actual enrollment

12

Study type

Interventional

Age

20 Years - 45 Years

Date

Study Start Date: 01 Nov 2008
Primary Completion Date: -
Study Completion Date: 01 Feb 2009

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria